Merck & Co., Inc. (MRK)
|Net Income (ttm)||7.07B|
|Trading Day||March 8|
|Day's Range||73.40 - 75.56|
|52-Week Range||63.76 - 86.48|
Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI...
Merck (MRK) announces encouraging preliminary data from a mid-stage study evaluating its oral COVID-19 antiviral candidate, molnupiravir, evaluating it in non-hospitalized adults with symptoma...
U.S. President Biden will meet with the chief executives of Johnson & Johnson and Merck & Co Inc at the White House on Wednesday after the companies recently announced a COVID-19 vaccine manuf...
Merck stock popped Monday after its Ridgeback Biotherapeutics-partnered Covid-19 treatment showed promise in an interim analysis of a Phase 2 test. But Merck stock is still under pressure.
Merck & Co Inc (NYSE: MRK) and its collaborating partner Ridgeback Biotherapeutics LP reported preliminary results from Phase 2a study evaluating molnupiravir, an experimental antiviral drug a...
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
MIAMI & KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupi...
Merck (MRK) closed the most recent trading day at $73.13, moving +1.33% from the previous trading session.
Demand for Covid Products to Remain High: Merck KGaA CEO
Mar.04 -- Merck KGaA Chief Executive Officer Stephan Oschmann says that while the Covid-19 vaccine rollout is “encouraging,” he expects the virus “will be endemic in future.” Oschmann spoke on...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Begins Tender Offer to Acquire Pandion Therapeutics
We were cautious during the pandemic, but our businesses performed well: Merck KGaA CEO
Stefan Oschmann, CEO of Merck KGaA, discusses the company's full-year earnings.
Merck KGaA, Darmstadt, Germany moves the Silicon Valley Innovation Hub to San Jose's Intermolecular site
SAN JOSE, Calif., March 4, 2021 /PRNewswire/ -- Intermolecular, Inc. ("Intermolecular"), the trusted partner for materials innovation and a wholly-owned subsidiary of Merck KGaA, Darmstadt, Ge...
Germany's Merck KGaA predicted further earnings gains in 2021 as an effort by the pharma industry to ready treatments and vaccines against the coronavirus bolsters demand for its supplies for ...
Merck, Bristol Myers and Pfizer...which one is most attractive?
The "Halftime Report" traders answer viewer questions in #AskHalftime.
Travel stocks will benefit from a return to normalcy
Cramer on Merck, J&J Covid vaccine manufacturing partnership
“What this means is that Americans are going to get shots in the arm faster, and we're very excited about the potential impact that this can have overall on the situation,” Johnson & Johnson C...
Merck (MRK) will use its existing facilities to manufacture and supply J&J's newly approved COVID-19 vaccine.
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at the Barclays Global Healthcare Conference
Johnson & Johnson CEO on working with Merck to produce 100 million vaccines by summer
"The real war here is against Covid-19 and I couldn't think of a better partner than Merck, a company with an incredibly strong reputation," Johnson & Johnson CEO Alex Gorsky said of his compa...
Johnson & Johnson CEO on Merck vaccine partnership: 'Extraordinary times take extraordinary efforts'
Johnson & Johnson CEO Alex Gorsky discussed on Tuesday the company's unprecedented partnership with rival Merck to boost production of its Covid-19 vaccine.
Merck's J&J partnership reminiscent of penicillin in 1942
CNBC's Meg Tirrell on the partnership between Merck and Johnson & Johnson partnership to manufactures J&J's Covid vaccine. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Se...
Merck to Help Produce Johnson & Johnson's COVID-19 Vaccine; BARDA to Provide Merck With Funding to Expand Merck's Manufacturing Capacity for COVID-19 Vaccines and Medicines
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Help Produce Johnson & Johnson's COVID-19 Vaccine; BARDA to Provide Merck with Funding to Expand Merck's Manufacturing Capacity
Merck will help rival drugmaker Johnson & Johnson produce its single-dose coronavirus vaccine, the White House said Tuesday. The two pharmaceutical giants have reached a “historic manufacturin...
Johnson and Johnson will get help from Merck to produce COVID-19 vaccines
#Johnson&Johnson #coronavirusvaccine #COVID19vaccine Dr. Andre Campbell, Professor of Surgery of UCSF & ICU Physician and Trauma Surgeon at Zuckerberg San Francisco General Hospital, joins Yah...
Merck will reportedly step in to help Johnson & Johnson manufacture its coronavirus vaccine in a deal that binds two rival vaccine stocks. J&J is reportedly behind in production.
Coronavirus vaccine: Merck will help produce Johnson & Johnson COVID-19 vaccine
#coronavirusvaccine #COVID19vaccine #coronavirus Harvard Medical School Professor Dr. Ali Raja discusses vaccine distribution with Yahoo Finance's Aikiko Fujita and Zack Guzman.
The United States is using the Defense Production Act to equip drugmaker Merck & Co's plants to make Johnson & Johnson's just approved COVID-19 vaccine, White House press secretary Jen Psaki s...
How Merck could assist J&J's covid vaccine manufacturing efforts
CNBC's Meg Tirrell reports that President Biden is set to announce later this afternoon that Merck will help make rival Johnson & Johnson's Covid vaccine.
Merck & Co Inc will help make rival Johnson & Johnson's single-shot COVID-19 vaccine in a partnership set to be announced on Tuesday by U.S. President Joe Biden, a White House official said.
Jim Cramer: Merck helping J&J with manufacturing is a sign 'we're going to beat this thing'
President Joe Biden will announce Tuesday that pharmaceutical giant Merck will help make Johnson & Johnson's Covid-19 vaccine, a senior administration official confirmed to NBC News. CNBC's Ji...
Biden to announce Merck will aid in manufacturing of J&J Covid vaccine
President Joe Biden will announce Tuesday that pharmaceutical giant Merck will help make Johnson & Johnson's Covid-19 vaccine, a senior administration official confirmed to NBC News. CNBC's Be...
U.S. President Joe Biden will announce that Merck & Co (NYSE: MRK) will help manufacture its rival Johnson & Johnson's (NYSE: JNJ) newly authorized coronavirus vaccine to boost the supply, Was...
Merck Announces Fifth Round of Global Grants to Tackle Maternal Mortality and Promote Health Equity Worldwide
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Fifth Round of Global Grants to Tackle Maternal Mortality and Promote Health Equity Worldwide
New funds, new partners: Seattle's Presage Biosciences announced $13 million in funding as well new collaborations with biotech giant Merck and California-based Maverick Therapeutics.
PANDION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pandion Therapeutics, Inc. - PAND
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pandion ...
Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US
The FDA has accepted Merck & Co Inc's (NYSE: MRK) marketing application seeking approval for gefapixant, for review. The selective P2X3 receptor antagonist is being developed to treat refracto...
Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to develop and commercialise Xevinapant for head and neck cancer.
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Accepts Merck's Gefapixant New Drug Application for Review
Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
DARMSTADT, Germany, March 1, 2021 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a worldwide in-licensing agreement with Debiopharm, ...
Hillman Capital Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.
Merck & Co Inc (NYSE: MRK) had reported a significant snag in its latest annual filing (10K), wherein the company has received feedback from the FDA regarding its COVID-19 drug, MK-7110. The a...
Is Merck stock a buy as the company plans to buy Pandion Therapeutics, an early-stage biotech testing drugs for autoimmune diseases? Check out Merck stock chart and materials.
Here's how you can take advantage of the latest sell-off in a stalwart pharma stock.
You'd vault into the air too if a big-name pharmaceutical paid a high premium for your stock.
Seeking to beef up a product line dominated by the cancer drug Keytruda, Merck & Co. Inc. (NYSE:MRK) has made another in a series of acquisitions. The Kenilworth, New Jersey-based drug giant i...
MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health Completes Acquisition of Poultry Sense Limited
Merck & Company provides healthcare solutions worldwide. The company offers therapeutic for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; ... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, Merck's revenue was $47.99 billion, an increase of 2.46% compared to the previous year's $46.84 billion. Earnings were $7.07 billion, a decrease of -28.20%.
According to 23 analysts, the average rating for Merck stock is "Buy." The 12-month stock price forecast is 96.33, which is an increase of 29.39% from the latest price.